CDT
CDT Equity Inc.1.7100
-0.0500-2.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.79MP/E (TTM)
-Basic EPS (TTM)
-179.34Dividend Yield
0%Recent Filings
8-K
1-for-25 reverse split approved
CDT Equity Inc. filed for a 1-for-25 reverse stock split, effective March 26, 2026 at 5:00 p.m. ET, slashing outstanding shares to approximately 4,722,450. Trading resumes adjusted on Nasdaq under CDT on March 27. No fractional shares; cash paid instead. Reverse splits help Nasdaq compliance, yet stock price effects remain uncertain.
8-K
Stockholders approve key proposals
CDT Equity stockholders overwhelmingly approved all seven proposals at the March 17, 2026 special meeting, greenlighting massive warrant exercises up to 113.7 million shares, a potential reverse stock split up to 1-for-100, doubling authorized shares to 500 million, and redomestication to the Cayman Islands. Quorum cleared with over one-third turnout. Board now holds reverse split discretion.
8-K
ELOC amended, $556K note issued
CDT Equity amended its ELOC floor price to $0.60 on March 3, 2026, raising the maximum issuable shares to 41,666,667 pending stockholder approval. It also issued a senior secured convertible note to Ascent Partners with $555,556 principal for $500,000 proceeds at 10% interest, maturing July 3, 2026, secured by assets and a guaranty. Conversions hinge on approval by May 3. Dilution awaits shareholders.
8-K
Acquires 20% Sarborg stake
CDT Equity acquired 20% of Sarborg Limited on February 19, 2026, issuing 598,006 common shares and pre-funded warrants for 109,978,918 shares, plus deferred $8 million cash payable after raising $20 million via at-the-market facility. It extended consulting deals with NJS and Thesprogen by 12 months each, paying $150,000 and $245,000 in stock. Warrants await stockholder approval. Related-party ties noted.
8-K
Secures $25M ELOC facility
CDT Equity inked a $25M equity line deal with Ascent Partners on January 16, 2026, letting it sell common stock at 94-97% of VWAP over 36 months, capped per draw at $750K regular or $5M expanded. It issued 204,031 commitment shares, payable by April 16 or registration effectiveness, for working capital. Yet dilution looms if stock dips below $1.35 floor.
IPO
Employees
Sector
Industry
ACET
Adicet Bio, Inc.
0.47-0.03
CELZ
Creative Medical Technology Hol
2.09-0.03
CLDX
Celldex Therapeutics, Inc.
26.68-0.41
CLYM
Climb Bio, Inc.
4.62+0.81
CUBT
CURATIVE BIOTECHNOLOGY INC.
0.01+0.00
CYDY
CytoDyn Inc.
0.32+0.02
EQ
Equillium, Inc.
1.21-0.01
GDTC
CytoMed Therapeutics Limited
1.62+0.02
IMA
ImageneBio, Inc.
6.25+0.08
SABS
SAB Biotherapeutics, Inc.
3.99-0.01